eLabNext and ABI-LAB Announce Strategic Partnership to Foster Innovation in Life Sciences
July 26, 2024 11:59 ET
|
eLabNext; ABI-LAB
eLabNext and ABI-LAB have announced a strategic alliance aimed at driving innovation and supporting the growth of life sciences startups.
Cytokinetics to Announce Second Quarter Results on August 8, 2024
July 25, 2024 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 8, 2024 at...
[Latest] US Biotechnology Market Size/Share Worth USD 1797.8 Billion by 2033 at a 12.3% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
July 25, 2024 13:30 ET
|
Custom Market Insights
Austin, TX, USA, July 25, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “US Biotechnology Market Size, Trends and Insights By Technology...
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
July 25, 2024 08:30 ET
|
FN Media Group LLC
PALM BEACH, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The fibromyalgia treatment market has witnessed positive growth trends over the past few years. There is higher...
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
July 25, 2024 06:30 ET
|
Ocugen
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering,...
TransCode Therapeutics, Inc. Announces Closing of Public Offering
July 24, 2024 16:05 ET
|
TransCode Therapeutics, Inc.
Boston, MA — July 24, 2024 — TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed to
NeOnc Initiates Cohort 3 in Phase 1 Clinical Trial of NEO212™, a Patented Novel Hybrid Drug Designed to Deliver ‘Double Punch’ Against Malignant Brain Tumors
July 24, 2024 11:15 ET
|
NeOnc Technologies Holdings, Inc.
NEO212™ completes initial two cohorts of Phase 1 study under FDA Investigative New Drug (IND).Study tests the safety of NeOnc’s patented novel drug, NEO212™, which is the bioconjugation of its leading...
Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024
July 23, 2024 16:05 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, July 23, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report second...
Global Forensic Technologies and Services Market Insights, 2024-2030 - Rise in Gun Violence Driving Demand for Forensic Ballistics
July 23, 2024 12:46 ET
|
Research and Markets
Dublin, July 23, 2024 (GLOBE NEWSWIRE) -- The "Forensic Technologies and Services - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market...
TransCode Therapeutics, Inc. Announces Pricing of Public Offering
July 22, 2024 22:30 ET
|
TransCode Therapeutics, Inc.
Boston, MA — July 22, 2024 — TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed t